Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- 30 Mar 2018 Planned initiation date changed from 1 Oct 2017 to 1 May 2018.
- 05 Dec 2016 According to a GW Pharmaceuticals media release, the company expects to initiate this trial in the third quarter of 2017.
- 31 Aug 2016 New trial record